| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 41 | 改変Ｇ６ＰＣをコードするアデノ随伴ウイルスベクターおよびその使用 | JP2017533845 | 2015-12-22 | JP2018501791A | 2018-01-25 | チョウ, ジャニス ジェイ. |
| ホスホヒドロラーゼ活性が増大している改変G6PC(グルコース−6−ホスファターゼ、触媒サブユニット)核酸およびグルコース−6−ホスファターゼ−α(G6Pase−α)酵素が記載される。アデノ随伴ウイルス(AAV)ベクターおよび改変G6Pase−αを発現する組換えAAVなどのベクターも記載される。開示のAAVベクターおよびrAAVは、糖原病、特に糖原病Ia型(GSD−Ia)およびその合併症の処置における遺伝子療法の適用のために使用され得る。 | ||||||
| 42 | 水性液体の増粘に有用なデンプン組成物 | JP2016569777 | 2015-05-27 | JP2017522401A | 2017-08-10 | シー． カーウッド クリストファー; ハル マーシャル; スケルディング ウィリアム; ヴィ． ウィーダーホールド マーヴィン |
| 本発明は、具体的に、例えば、嚥下障害を病んでいる人が使用するために、液体を増粘させるのに有用なデンプン製品及びデンプン組成物に関する。一態様において、本発明は、約1%〜約10%の範囲のヒドロキシプロピル化の程度;及び約400cP〜約3500cPの範囲のRVA粘度を有するアルファ化、ヒドロキシプロピル化デンプンであって;ここで、アルファ化、ヒドロキシプロピル化デンプンが牛乳中に容易に分散可能なアルファ化、ヒドロキシプロピル化デンプンを提供する。他の態様は、約1%〜約10%の範囲のヒドロキシプロピル化の程度;約400cP〜約3500cPの範囲のRVA粘度;及び約80%未満の相応する天然デンプンの表面タンパク質を有するアルファ化、ヒドロキシプロピル化デンプンを提供する。 | ||||||
| 43 | エンドペプチダーゼ活性を有するポリペプチド及びそれをコードするポリヌクレオチド | JP2013530759 | 2011-09-30 | JP5944908B2 | 2016-07-05 | ピーター エル.エステルガールド; カルステン ペー.センクセン; ティネ ホフ; ギッテ ベー.リングレブ |
| 44 | Techniques for the production of microparticles | JP2010518390 | 2008-07-24 | JP2010534563A | 2010-11-11 | ファン，ファン; マラコフ，マイケル |
| 溶媒中の高分子又は低分子の溶液を貧溶媒及び対イオンと接触させ、この溶液を冷却することによってマイクロスフェアが作製される。 このマイクロスフェアは、定められた大きさの医薬、ニュートラシューティカル（ｎｕｔｒａｃｅｕｔｉｃａｌｓ）、美容製品等の作製に有用である。
【選択図】なし |
||||||
| 45 | Microcapsule | JP2002580739 | 2002-04-10 | JP2004529760A | 2004-09-30 | ニーナ ミューゼウス イェンセン; ストラルップ アネット クリステンセン; カリン メイェル ハンセン; カルステン リンガールト ハンセン; モルテン モール ハンセン; アンデルス ヴァグネ ペデルセン; スザンヌ リュンド マドセン |
| ペクチン物質を、エステラーゼ（Ｅ．Ｃ．３．１)、グルコシダーゼ（Ｅ．Ｃ．３．２)、ペプチダーゼ（Ｅ．Ｃ．３．４)、プロテアーゼ（Ｅ．Ｃ．３．４）及びリアーゼ（Ｅ．Ｃ．４）から成る群から選ばれる一種以上の酵素で処理する事によって得られるマトリックス材料中に埋め込まれた活性物質を含むマイクロカプセル、マイクロカプセルを製造する方法及びその様なマイクロカプセルを含む製品。 | ||||||
| 46 | Stable water-in-oil emulsion | JP52673595 | 1995-04-18 | JPH08512359A | 1996-12-24 | ルッポ エデンス; パリドン ペートルス アンドレアス ファン; ディルク メイイェール |
| (57)【要約】 本発明は、次の成分を含む安定した油中水エマルションについて述べている。 即ち、成分とは、水、油、重要な不安定化合物、安定化剤及び乳化剤である。 水相中に存在する該不安定化合物は、安定化剤を加えることにより安定する。 このとき、安定化剤は、ポリオールが好ましい。 特定の乳化剤により、多量のポリオール存在下で、安定したエマルションを生じることが述べられている。 | ||||||
| 47 | Anti-metalloprotease antibody for diagnosis and treatment of cancers | US15116487 | 2015-02-04 | US10023653B2 | 2018-07-17 | Martin Lackmann; Peter W. Janes; Lakmali Atapattu Mudiyanselage; Andrew M. Scott; Dimitar B. Nikolov; Nayanendu Saha |
| Expression of proteolytically active, high molecular weight ADAM protease is relatively increased in tumor cells that also express the putative tumor stem cell marker CD133. An antibody or antibody fragment such as 8C7 monoclonal antibody may be used to selectively bind to proteolytically active, high molecular weight ADAM10 protease to thereby detect tumor cells and also as a therapeutic agent for treating cancers, tumors and other malignancies inclusive of leukemia, lymphoma, lung cancer, colon cancer, adenoma, neuroblastoma, brain tumor, renal tumor, prostate cancer, sarcoma and/or melanoma. | ||||||
| 48 | CONTROLLED-RELEASE AND STRATIFIED CYCLODEXTRIN INCLUSION COMPLEX VEHICLES | US15285264 | 2016-10-04 | US20170224842A1 | 2017-08-10 | Al Czap |
| The invention provides cyclodextrin inclusion complex delivery vehicles, in which the cyclodextrin inclusion complex is provided together with enzyme having a cyclodextrin-degrading activity capable of digesting the cyclodextrin, so that upon delivery of the vehicle to a target the enzyme is activated and releases the guest molecule from the cyclodextrin cavity. In alternative aspects, these cyclodextrin inclusion complex delivery vehicles are for example provided in the form of medicaments, food ingredients, medical food ingredients, nutritional supplement ingredients, dietary supplement ingredients, herbicides, insecticides, fungicides, animal repellents, pheromones, plant growth regulators, fragrances, fabrics or packaging materials. | ||||||
| 49 | SPINAL CATHETER HAVING MULTIPLE OBSTRUCTION-CLEARING FEATURES | US15364377 | 2016-11-30 | US20170095658A1 | 2017-04-06 | Stephen T. PYLES; Daniel A. GRAUBERT |
| A spinal catheter for insertion into the epidural space of a human or animal subject includes first and second lumens. A pressurized fluid can be discharged through the first lumen directly onto a tissue obstruction to form a partial/pilot or full/final opening in the tissue obstruction. If a full opening was not formed sufficient for passage of the stimulator lead, the distal-end portion of the stimulator lead can be inserted into the partial opening and then a pressurized fluid can be delivered through the second lumen and into a distensible balloon for expanding the balloon to clear the tissue obstruction sufficient for passage of the stimulator lead. In this way the catheter can be advanced past a tissue obstruction and into place for use within the epidural space, without having to remove and reinsert multiple surgical implements. | ||||||
| 50 | ANTI-METALLOPROTEASE ANTIBODY FOR DIAGNOSIS AND TREATMENT OF CANCERS | US15116487 | 2015-02-04 | US20170008976A1 | 2017-01-12 | Martin LACKMANN; Peter W. JANES; Lakmali Atapattu MUDIYANSELAGE; Andrew M. SCOTT; Dimitar B. NIKOLOV; Nayanendu SAHA |
| Expression of proteolytically active, high molecular weight ADAM protease is relatively increased in tumour cells that also express the putative tumour stem cell marker CD133. An antibody or antibody fragment such as 8C7 monoclonal antibody may be used to selectively bind to proteolytically active, high molecular weight ADAM10 protease to thereby detect tumour cells and also as a therapeutic agent for treating cancers, tumours and other malignancies inclusive of leukemia, lymphoma, lung cancer, colon cancer, adenoma, neuroblastoma, brain tumour, renal tumour, prostate cancer, sarcoma and/or melanoma. | ||||||
| 51 | Methods and compositions using a Klotho-FGF23 fusion polypeptide | US14531620 | 2014-11-03 | US09475857B2 | 2016-10-25 | David Glass; Shou-Ih Hu |
| The present invention is directed to methods, kits and compositions for preventing or treating age-related conditions or metabolic disorders. The Klotho fusion polypeptides of the invention include at least a Klotho protein or an active fragment thereof. In one embodiment, the fusion polypeptide comprises a Klotho polypeptide, a FGF (such as FGF23) and (optionally) a modified Fc fragment. The Fc fragment can, for example, have decreased binding to Fc-gamma-receptor and increased serum half-life. The Klotho fusion proteins are useful in the treatment and prevention of a variety of age-related conditions and metabolic disorders. In another embodiment, the fusion polypeptide comprises a FGF (such as FGF23) and a modified Fc fragment. | ||||||
| 52 | METHODS AND FEED SUPPLEMENTS FOR IMPROVING NUTRITION INTAKE OF MEAT-TYPE POULTRIES | US14955820 | 2015-12-01 | US20160158326A1 | 2016-06-09 | Marc DE BEER; Chris PROVINCE; Nelson E. WARD |
| The present invention provides methods of improving growth performance, improving the efficiency of feed utilization, and increasing feed digestibility of poultry receiving animal feed. Composition of the multi-component enzyme mixture designed to achieve the same are also provided. | ||||||
| 53 | METHODS AND COMPOSITIONS USING KLOTO-FGF FUSION POLYPEPTIDES | US14531620 | 2014-11-03 | US20160031961A1 | 2016-02-04 | David GLASS; Shou-Ih HU |
| The present invention is directed to methods, kits and compositions for preventing or treating age-related conditions or metabolic disorders. The Klotho fusion polypeptides of the invention include at least a Klotho protein or an active fragment thereof. In one embodiment, the fusion polypeptide comprises a Klotho polypeptide, a FGF (such as FGF23) and (optionally) a modified Fc fragment. The Fc fragment can, for example, have decreased binding to Fc-gamma-receptor and increased serum half-life. The Klotho fusion proteins are useful in the treatment and prevention of a variety of age-related conditions and metabolic disorders. In another embodiment, the fusion polypeptide comprises a FGF (such as FGF23) and a modified Fc fragment. | ||||||
| 54 | Technology for the Preparation of Microparticles | US14742612 | 2015-06-17 | US20150359746A1 | 2015-12-17 | Michael P Malakhov; Fang Fang |
| Microspheres are produced by contacting a solution of a macromolecule or small molecule in a solvent with an antisolvent and a counterion, and chilling the solution. The microspheres are useful for preparing pharmaceuticals, nutraceuticals, cosmetic products and the like of defined dimensions. | ||||||
| 55 | Methods and compositions using Kloto-FGF23 fusion polypeptides | US13796711 | 2013-03-12 | US08932589B2 | 2015-01-13 | David Glass; Shou-Ih Hu |
| The present invention is directed to methods, kits and compositions for preventing or treating age-related conditions or metabolic disorders. The Klotho fusion polypeptides of the invention include at least a Klotho protein or an active fragment thereof. In one embodiment, the fusion polypeptide comprises a Klotho polypeptide, a FGF (such as FGF23) and (optionally) a modified Fc fragment. The Fc fragment can, for example, have decreased binding to Fc-gamma-receptor and increased serum half-life. The Klotho fusion proteins are useful in the treatment and prevention of a variety of age-related conditions and metabolic disorders. In another embodiment, the fusion polypeptide comprises a FGF (such as FGF23) and a modified Fc fragment. | ||||||
| 56 | Technology for the Preparation of Microparticles | US13874424 | 2013-04-30 | US20140099696A1 | 2014-04-10 | Michael P. Malakhov; Fang Fang |
| Microspheres are produced by contacting a solution of a macromolecule or small molecule in a solvent with an antisolvent and a counterion, and chilling the solution. The microspheres are useful for preparing pharmaceuticals, nutraceuticals, cosmetic products and the like of defined dimensions. | ||||||
| 57 | Methods of lysosomal storage disease therapy | US13253005 | 2011-10-04 | US08679478B2 | 2014-03-25 | Dwight D. Koeberl |
| Methods of treating a lysosomal storage disorder and methods of increasing cellular uptake of a lysosomal enzyme using β2 agonists or therapeutic agents that increase expression of receptors for a lysosomal enzyme. | ||||||
| 58 | COMPOUNDS | US13997017 | 2011-12-23 | US20130315959A1 | 2013-11-28 | Paolo Costantino; Roberto Adamo; Maria Rosaria Romano; Elisa Danieli; Francesco Berti; Emilia Cappelliti; Luigi Lay |
| The invention provides a synthetic C. difficile PS-II cell wall saccharide. The invention also provides a process for purifying C. difficile PS-II saccharide from C. difficile bacterial cells resulting in reduced contamination. The saccharides may be used in vaccines, particularly as conjugates with carrier proteins. | ||||||
| 59 | Methods and compositions using FGF23 fusion polypeptides | US12696693 | 2010-01-29 | US08420088B2 | 2013-04-16 | David Glass; Shou-Ih Hu |
| The present invention is directed to fusion polypeptides comprising Klotho protein or an active fragment thereof and FGF23 or an active fragment thereof. | ||||||
| 60 | Technology for the Preparation of Microparticles | US13250653 | 2011-09-30 | US20120141590A1 | 2012-06-07 | Michael Malakhov; Fang Fang |
| Microspheres are produced by contacting a solution of a macromolecule or small molecule in a solvent with an antisolvent and a counterion, and chilling the solution. The microspheres are useful for preparing pharmaceuticals, nutraceuticals, cosmetic products and the like of defined dimensions. | ||||||
QQ群二维码
意见反馈
意见反馈